Amazon, Warner Bros, and Dow rise premarket; Nio, Nike, HP fall

  • Investing.com
  • Stock Market News
Amazon, Warner Bros, and Dow rise premarket; Nio, Nike, HP fall
Credit: © Reuters.

Investing.com -- U.S. futures edged lower Monday, with investors still reeling from last week’s hawkish Federal Reserve meeting, while a U.S. government shutdown draws nearer.

Here are some of the biggest premarket U.S. stock movers today:

  • Amazon (NASDAQ: AMZN ) stock rose 0.5% after the tech giant announced plans to invest up to $4 billion in artificial intelligence group Anthropic, in an attempt to bolster its position in nascent AI technology.

  • Warner Bros Discovery (NASDAQ: WBD ) stock rose 2.1%, Netflix (NASDAQ: NFLX ) rose 0.8% and Walt Disney (NYSE: DIS ) rose 0.3% as these entertainment giants benefited from the news that Hollywood's writers union reached a preliminary labor agreement with major studios on Sunday, likely ending strikes that have halted most film and television production.

  • Nio (NYSE: NIO ) ADRs fell 6.8% after the Chinese EV manufacturer announced it was considering raising $3B from investors.

  • Nike (NYSE: NKE ) stock fell 1.4% after Jefferies downgraded the sportswear giant to ‘hold’ from ‘buy’, citing increased risk due to ongoing pressure on the wholesale channel and macroeconomic challenges in China.

  • HP (NYSE: HPQ ) stock fell 3.7% after Warren Buffett's Berkshire Hathaway (NYSE: BRKa ) sold nearly 4.8 million shares of the PC-maker.

  • Dow (NYSE: DOW ) stock rose 1.4% after JPMorgan upgraded its stance on the chemicals giant the company to ‘overweight’ from ‘neutral’, citing a robust balance sheet, a hefty dividend yield and ample upside.

  • Rocket Companies (NYSE: RKT ) stock rose 3.1% after CFRA upgraded the mortgage loan provider to ‘hold’ from ‘sell’, saying its diversified businesses and available liquidity resources position it well.

  • AstraZeneca (LON: AZN ) (NASDAQ: AZN ) ADRs rose 1.7% after Jefferies upgraded the pharmaceutical company to ‘buy’ from ‘neutral’, noting last week’s positive results from its new lung cancer drug.

  • Harmony Biosciences (NASDAQ: HRMY ) stock fell 3.1% after Goldman Sachs downgraded the biopharmaceutical company to ‘sell’ from ‘neutral’, seeing emerging risks to the durability of its revenue stream.

Add Chart to Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100
Please try another search